Apomorphine and diphasic dyskinesia.
Identifieur interne : 005273 ( Main/Merge ); précédent : 005272; suivant : 005274Apomorphine and diphasic dyskinesia.
Auteurs : F. Durif [France] ; D. Deffond ; G. Dordain ; M. TournilhacSource :
- Clinical neuropharmacology [ 0362-5664 ] ; 1994.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Levodopa.
- chemical , therapeutic use : Apomorphine, Levodopa.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- physiology : Circadian Rhythm.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
We report on three observations of parkinsonian patients with levo-dopa-induced diphasic dyskinesias, who received subcutaneous apomorphine to reduce the duration of abnormal movements. Apomorphine was effective in reducing the duration of diphasic dyskinesias at doses higher than the threshold doses necessary to induce an "on" phase (mean increase: 43%). However, after a few months of treatment, apomorphine was ineffective in stopping abnormal movements, even when doses were increased. In two patients, apomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon. Acute diurnal variations of the pharmacodynamic striatal response are suggested explanation for these clinical observations.
PubMed: 8149366
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001687
- to stream PubMed, to step Curation: 001646
- to stream PubMed, to step Checkpoint: 001646
- to stream Ncbi, to step Merge: 001D29
- to stream Ncbi, to step Curation: 001D29
- to stream Ncbi, to step Checkpoint: 001D29
Links to Exploration step
pubmed:8149366Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apomorphine and diphasic dyskinesia.</title><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name><affiliation wicri:level="1"><nlm:affiliation>Clinique Neurologique, Hôpital Fontamaure, CHU Clermont-Ferrand, Chamalières, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinique Neurologique, Hôpital Fontamaure, CHU Clermont-Ferrand, Chamalières</wicri:regionArea><wicri:noRegion>Chamalières</wicri:noRegion><wicri:noRegion>Chamalières</wicri:noRegion></affiliation></author><author><name sortKey="Deffond, D" sort="Deffond, D" uniqKey="Deffond D" first="D" last="Deffond">D. Deffond</name></author><author><name sortKey="Dordain, G" sort="Dordain, G" uniqKey="Dordain G" first="G" last="Dordain">G. Dordain</name></author><author><name sortKey="Tournilhac, M" sort="Tournilhac, M" uniqKey="Tournilhac M" first="M" last="Tournilhac">M. Tournilhac</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:8149366</idno><idno type="pmid">8149366</idno><idno type="wicri:Area/PubMed/Corpus">001687</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001687</idno><idno type="wicri:Area/PubMed/Curation">001646</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001646</idno><idno type="wicri:Area/PubMed/Checkpoint">001646</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001646</idno><idno type="wicri:Area/Ncbi/Merge">001D29</idno><idno type="wicri:Area/Ncbi/Curation">001D29</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D29</idno><idno type="wicri:doubleKey">0362-5664:1994:Durif F:apomorphine:and:diphasic</idno><idno type="wicri:Area/Main/Merge">005273</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Apomorphine and diphasic dyskinesia.</title><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name><affiliation wicri:level="1"><nlm:affiliation>Clinique Neurologique, Hôpital Fontamaure, CHU Clermont-Ferrand, Chamalières, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinique Neurologique, Hôpital Fontamaure, CHU Clermont-Ferrand, Chamalières</wicri:regionArea><wicri:noRegion>Chamalières</wicri:noRegion><wicri:noRegion>Chamalières</wicri:noRegion></affiliation></author><author><name sortKey="Deffond, D" sort="Deffond, D" uniqKey="Deffond D" first="D" last="Deffond">D. Deffond</name></author><author><name sortKey="Dordain, G" sort="Dordain, G" uniqKey="Dordain G" first="G" last="Dordain">G. Dordain</name></author><author><name sortKey="Tournilhac, M" sort="Tournilhac, M" uniqKey="Tournilhac M" first="M" last="Tournilhac">M. Tournilhac</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="ISSN">0362-5664</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Apomorphine (therapeutic use)</term><term>Circadian Rhythm (physiology)</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Female</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Circadian Rhythm</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report on three observations of parkinsonian patients with levo-dopa-induced diphasic dyskinesias, who received subcutaneous apomorphine to reduce the duration of abnormal movements. Apomorphine was effective in reducing the duration of diphasic dyskinesias at doses higher than the threshold doses necessary to induce an "on" phase (mean increase: 43%). However, after a few months of treatment, apomorphine was ineffective in stopping abnormal movements, even when doses were increased. In two patients, apomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon. Acute diurnal variations of the pharmacodynamic striatal response are suggested explanation for these clinical observations.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005273 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005273 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:8149366
|texte= Apomorphine and diphasic dyskinesia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:8149366" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |